The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1681
ISSUE1681
July 24, 2023
Zavegepant (Zavzpret) for Acute Treatment of Migraine
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Zavegepant (Zavzpret) for Acute Treatment of Migraine
July 24, 2023 (Issue: 1681)
The FDA has approved zavegepant nasal spray
(Zavzpret – Pfizer) for acute treatment of migraine
with or without aura in adults. Zavzpret is the first
nasal spray formulation of a calcitonin gene-related
peptide (CGRP) receptor antagonist...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.